Happy #DarkMatterDay#!🌌 Researchers from the @ucsc used @ORNL's Summit supercomputer back in 2023 to run more than 1,000 high-resolution simulations of the Lyman-Alpha Forest — lines of diffuse gas in the cosmos. 🔗 #BigScience#

Arriving in 2028, Discovery will usher in a new era of scientific computing.🚀 ORNL’s Bronson Messer explains why Discovery represents an exciting new chapter in leadership computing at @ORNL. 🔗More details: @HPE @AMD #BigScience#

#PostdocAppreciationWeek# is a great opportunity to highlight the innovative work of postdoctoral researchers like Chao Lu, whose research is exploring new possibilities at the intersection of quantum computing and scientific discovery. ⚛️ #QuantumComputing# #BigScience#

👏 @ORNL has received the @IEEEorg Quantum Technical Community Distinguished Synergy Award, recognizing ORNL’s commitment to advancing quantum science through collaboration.🏆 🔗 Read more: #BigScience# #QuantumComputing#

October 18 marks #WorldExascaleDay#, reflecting the 10¹⁸ calculations per second that define exascale computing.✨ At @OLCFGOV, @ORNL's Frontier is advancing scientific discovery. In 2028, ORNL's Discovery will take us further.🚀 🔗 #BigScience#

🎶 Workin’ 9 to 5? Not at the OLCF.😉 While Dolly Parton made “9 to 5” famous, OLCF’s leadership-class supercomputers work 24/7, running jobs that advance scientific discovery. Because supercomputing doesn’t clock out at 5. ⏰ Happy #DollyPartonDay#! 🦋 #BigScience# @AMD @HPE

Big science creates impact far beyond the laboratory. Explore ORNL’s impact and learn how scientific capabilities in East Tennessee translate into innovation and economic opportunity nationwide in the 2025 Economic Impact Report. Read now ⬇️

PULSE BIOSCIENCES – STRONG THYROID TREATMENT RESULTS $PLSE 86% of patients achieved over 50% thyroid nodule volume reduction at six months. Median nodule volume reduction reached an impressive 72%. Significant improvements reported in patients' quality of life. No serious adverse events reported across 43 patients at three U.S. clinical sites.

Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.

Colossal Biosciences' mammoth has slipped from 2028 to the early 2030s. Their CEO's phrasing: "not 2036, but not 2030 either." The reason is the interesting part. The original plan targeted around 65 genes to convert an Asian elephant genome into something mammoth-like. As they analysed more ancient DNA from better-preserved Siberian specimens, that number went up to about 85 & Lamm says it could move again. 🧬 Traits like dense fur & cold adaptation turned out to depend on more genetic machinery than the initial analysis suggested. That's a normal result in genomics. Complex traits are rarely one gene doing one job & the more closely you look, the more contributors you find. The rest of the timeline is biology you can't compress. Elephant gestation runs about 22 months. Asian elephants are endangered, so using them as surrogates carries regulatory hurdles Colossal hasn't cleared. Even with a viable embryo tomorrow, the calf is nearly two years out. Worth keeping the honest framing that outside scientists keep raising: this produces a gene-edited Asian elephant with mammoth traits, not a mammoth. 🦣 As one put it, you might alter the hair pattern & cold tolerance, but you're changing an elephant. The spin-off technologies may end up mattering more than the animal — artificial womb research, multiplex editing, ancient DNA assembly. Colossal has spun out healthcare companies off the back of it. A slipping deadline isn't the scandal here. Discovering the problem is harder than you thought is what the work actually looks like.